Regional and Country Priorities for vaccine research

Angela Hwang

A new mechanism is being established under Immunization Agenda 2030 (IA2030) to identify regional and country priorities for vaccine research and development (R&D). These priorities will inform Monitoring and Evaluation (M&E) for IA2030. They will also be disseminated widely to enable greater coordination among funders, researchers, vaccine developers, vaccine implementers, and other stakeholders.

The first question being addressed is What are regional and country priorities for new vaccine product R&D for endemic pathogens? Once established, this mechanism can be used for additional questions of interest to regional and global stakeholders.

For more information, email This email address is being protected from spambots. You need JavaScript enabled to view it..

Context and results

TitleAuthorYearTypeLanguage
Partnering with regions and countries to identify priority pathogens for vaccines, December 2023Vaccine Prioritization & Platforms Team2023PresentationEnglish
Partnering with regions and countries to identify priority pathogens for vaccines, October 2022Vaccine Prioritization & Platforms Team2022PresentationEnglish

Methods

TitleAuthorYearTypeLanguage
Partnering with regions and countries to identify priority pathogens for vaccines: Update on survey preparation and dissemination, 5 December 2022Vaccine Prioritization & Platforms Team2022PresentationEnglish
Vaccine R&D Priorities: Initial Landscaping and Proposed Methods, for PDVAC inputVaccine Prioritization & Platforms Team2022DocumentEnglish
Vaccine R&D Priorities: Survey Preparation and Launch, for PDVAC inputVaccine Prioritization & Platforms Team2022DocumentEnglish
Vaccine R&D Priorities: Survey Progress and Preliminary Results, for SAGE inputVaccine Prioritization & Platforms Team2023DocumentEnglish
Vaccine R&D Priorities: Vaccine Use Cases and Action Categories, for PDVAC input December 2023Vaccine Prioritization & Platforms Team2024DocumentEnglish